About Candel

The cancer treatment paradigm has shifted dramatically over the last decade, providing evidence that the immune system can be reactivated against a patient’s tumor. However, most patients do not achieve stable disease remission with currently available immunotherapies.

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications.

Candel’s products are designed to significantly improve survival while maintaining quality of life – from early- to late-stage disease.

Our PURPOSE

to save, extend and improve the lives of patients through oncolytic viral immunotherapies.

Our PLAN

to harness the power of our proprietary virus-based approaches and elicit a broad, potent immune response against solid tumors and their metastases.

OUR LEADERSHIP

is made up of renowned drug developers, oncolytic viral immunotherapy experts, oncologists, immunologists and biotech business leaders. Candel is built on excellent science, and our experienced team is helping translate its full promise to patients.

Paul Peter Tak, M.D., Ph.D. FMedSci

President & Chief
Executive Officer

Estuardo Aguilar-Cordova, M.D., inf., Ph.D.

Founder & Chief
Scientific Officer

Laura K. Aguilar, M.D., Ph.D.

Chief Medical Officer

Nathan Caffo

Chief Business Officer

John Canepa

Chief Financial Officer

Susan Stewart, J.D.

Chief Regulatory Officer

Chris Matheny, PharmD, Ph.D.

Vice President, Development Leader

BOARD OF DIRECTORS

Paul B. Manning

Chair of the Board

Estuardo Aguilar-Cordova,
M.D., inf., Ph.D.

Edward J. Benz, Jr. M.D.

Shaan Gandhi, M.D., D. Phil

Chris Martell

Udi Meirav, Ph.D.

Alan E. Smith, Ph.D, FRS, CBE

Paul Peter Tak, M.D., Ph.D. FMedSci

RESEARCH ADVISORY BOARD

Edward J. Benz, Jr. M.D.

President & CEO Emeritus
Dana-Farber Cancer Institute

Roy Herbst, M.D., Ph.D.

Chief of Medical Oncology
Yale Cancer Center

Philip Kantoff, M.D.

Chief, Department of Medicine
Memorial Sloan Kettering Center

Padmanee Sharma, M.D., Ph.D.

Professor of Genitourinary Medical Oncology and Immunology
MD Anderson Cancer Center

Henry Brem, M.D.

Director, Department of Neurosurgery
Professor of Neurosurgery
Johns Hopkins University

Elizabeth Jaffee, M.D.

Deputy Director
Sidney Kimmel Cancer Center at
Johns Hopkins University

James P. Allison, Ph.D.

Chief of the Department of Immunology
MD Anderson Cancer Center
Director of the Parker Institute for Cancer Research

SCIENTIFIC ADVISORS

Charu Aggarwal, M.D., MPH
Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania

Steven M. Albelda, M.D.
Professor of Medicine and Vice Chief, Pulmonary, Allergy and Critical Care Division, Thoracic Research Laboratory, University of Pennsylvania

Mark Bloomston, M.D.
Medical Director, South Florida Surgical Oncology

E. Antonio Chiocca, M.D., Ph.D.
Chair, Department of Neurosurgery Brigham and Women’s Hospital and Professor, Harvard Medical School

Scott Eggener, M.D.
Professor of Surgery and Radiology, Vice Chair of Urology, Director High Risk and Advanced Prostate Cancer Clinic, University of Chicago

Adam Kibel, M.D.
Chief, Division of Urology Brigham and Women’s Hospital and Professor, Harvard Medical School

Tri Le, M.D.
Assistant Professor, Medicine, Hematology and Oncology, University of Virginia

Daniel H. Sterman, M.D.
Professor and Director, Pulmonary, Critical Care and Sleep Medicine, NYU Langone Health

Patrick Y. Wen, M.D.
Director, Center for Neuro-Oncology Dana-Farber Cancer Institute and Professor, Neurology, Harvard Medical School

Sunil Singhal, M.D.